|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2006-5-29
|
|
pubmed:abstractText |
Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma. Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AirdSuzanS,
pubmed-author:ChapmanPaul BPB,
pubmed-author:HoughtonAlan NAN,
pubmed-author:HwuWen-JenWJ,
pubmed-author:KrownSusan ESE,
pubmed-author:LambLynne ALA,
pubmed-author:LivingstonPhilip OPO,
pubmed-author:MenellJennifer HJH,
pubmed-author:PanageasKatherine SKS,
pubmed-author:WilliamsLinda JLJ,
pubmed-author:WolchokJedd DJD
|
|
pubmed:copyrightInfo |
Copyright (c) 2006 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2445-51
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16639739-Adult,
pubmed-meshheading:16639739-Aged,
pubmed-meshheading:16639739-Aged, 80 and over,
pubmed-meshheading:16639739-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16639739-Dacarbazine,
pubmed-meshheading:16639739-Eye Neoplasms,
pubmed-meshheading:16639739-Female,
pubmed-meshheading:16639739-Follow-Up Studies,
pubmed-meshheading:16639739-Humans,
pubmed-meshheading:16639739-Interferon-alpha,
pubmed-meshheading:16639739-Male,
pubmed-meshheading:16639739-Melanoma,
pubmed-meshheading:16639739-Middle Aged,
pubmed-meshheading:16639739-Mouth Neoplasms,
pubmed-meshheading:16639739-Polyethylene Glycols,
pubmed-meshheading:16639739-Recombinant Proteins,
pubmed-meshheading:16639739-Remission Induction,
pubmed-meshheading:16639739-Skin Neoplasms,
pubmed-meshheading:16639739-Survival Rate
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. wenjhwu@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
